If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
RESEARCH TRIANGLE PARK, N.C.–(HSMN NewsFeed)–Quintiles Transnational Corp. and Allergan, Inc. (NYSE: AGN ) today announced an agreement under which Quintiles will co-promote Allergan’s SANCTURA XR(R) (trospium chloride extended release capsules), an anti…
Biopharmaceuticals, Urology
Quintiles Transnational, Allergan, SANCTURA XR, trospium, overactive bladder
Posts from ‘September, 2009’
Quintiles and Allergan Announce Co-Promotion for Sanctura XR(R)
Results from Abbott’s PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease
SAN FRANCISCO, Sept. 24 (HSMN NewsFeed) — Abbott (NYSE: ABT ) today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial. PROSPECT is the first pro…
Devices, Cardiology
Abbott, vulnerable plaque, PROSPECT study, atherosclerosis
Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcano’s VH(R) IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks
SAN FRANCISCO, Sept. 24 (HSMN NewsFeed) — Volcano Corporation (Nasdaq: VOLC ), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, announced today imaging results fr…
Devices, Interventional Cardiology
Volcano, vulnerable plaque, PROSPECT study, atherosclerosis, IVUS
Dynatronics Expands Nationwide Direct Sales Force by 25 %
SALT LAKE CITY, Sept. 24 (HSMN NewsFeed) — Dynatronics Corporation (Nasdaq: DYNT ) announced it has added 10 new revenue representatives to its nationwide direct sales force, bringing the total to Fifty - a 25 % increase. "We’re thrilled to be …
Devices
Dynatronics
ULURU Inc. Presents Data on Negative Pressure Related to Altrazeal(TM) at the Diabetic Limb Salvage Conference in Washington, D.C.
ADDISON, Texas, Sept. 24 (HSMN NewsFeed) — ULURU Inc. (NYSE Alternext: ULU) announced today the presentation of important medical data and research at the 2009 Diabetic Limb Salvage (DLS) Conference in Washington, D.C. One poster presentation demonstra…
Devices, Wound Care
ULURU, Altrazeal, Nanoflex
Abbott’s XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
At One Year, XIENCE V Demonstrates: - Statistical Superiority on Primary Endpoint of Target Lesion Failure, with a 38 Percent Reduction Compared to TAXUS - 74 % Reduction in Stent Thrombosis (Blood Clots) Compared to TAXUS - Low Event Rat…
Devices, Interventional Cardiology
Abbott, SPIRIT IV trial, XIENCE V, drug eluting stent
Cook Incorporated Wins Patent Infringement Appeal Filed By Edwards Lifesciences
BLOOMINGTON, Ind.–(HSMN NewsFeed)–The United States Court of Appeals for the Federal Circuit today affirmed the previous ruling of the United States District Court for the Northern District of California that Cook Incorporated does not infringe on Edward…
Devices, Interventional, Litigation
Cook Pharmaceutical, Edwards Lifesciences, endovascular stent-graft, aortic aneurysm
Cook Medical’s Advanced NavAlign Delivery System for IVC Filters Adds Procedural Speed, Control and Accuracy
New Design Simplifies Jugular Deployment, Minimizes Trauma, Compatible with Full Line of IVC Filters SAN FRANCISCO–(HSMN NewsFeed)–Physicians can now navigate even the most tortuous anatomy with greater speed and safety with the next-generation inferi…
Devices
Cook Medical, NavAlign, vena cava filter, thromboembolism, pulmonary embolism
FAME Trial Two-Year Follow-Up Results Demonstrate Continued Reduction in Risk of Death or Heart Attack When Physicians Use St. Jude Pharmaceutical Fractional Flow Reserve Technology Prior to Implanting Coronary Stents
Trial Demonstrates an FFR-Guided Strategy to Treat Multivessel Coronary Artery Disease Both Improves Outcomes and is Cost-Saving Compared to Procedures Using Angiography Alone ST. PAUL, Minn., Sept. 23–(HSMN NewsFeed)–St. Jude Clinical, Inc. (NYSE:STJ …
Devices, Interventional Cardiology
St. Jude Medical, FAME Trial, Fractional Flow Reserve, PressureWire
BurnsAdler Partners With 3 Rivers Pharmaceuticals to Commercialize Infergen(R) in Brazil and Chile
CHARLOTTE, NC and WARRENDALE, PA., Sept. 23 - (HSMN NewsFeed) - BurnsAdler Pharmaceuticals, Inc. ("BurnsAdler") announced today that it has entered into a long-term licensing and supply agreement with 3 Rivers Pharmaceuticals, LLC ("Thre…
Biopharmaceuticlas, Licensing
BurnsAdler Pharmaceuticals, Three Rivers Pharmaceuticals, Infergen
